| 3.01 0.16 (5.61%) | 01-23 14:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.9 | 1-year : | 4.55 |
| Resists | First : | 3.33 | Second : | 3.9 |
| Pivot price | 2.6  |
|||
| Supports | First : | 2.66 | Second : | 2.25 |
| MAs | MA(5) : | 2.81 |
MA(20) : | 2.55 |
| MA(100) : | 2.83  |
MA(250) : | 2.97 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 64.9 |
D(3) : | 64 |
| RSI | RSI(14): 66.6 |
|||
| 52-week | High : | 3.89 | Low : | 2.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NRXS ] has closed above the upper band by 1.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 32.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.23 - 3.25 | 3.25 - 3.26 |
| Low: | 2.75 - 2.76 | 2.76 - 2.77 |
| Close: | 2.83 - 2.85 | 2.85 - 2.87 |
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Tue, 21 Jan 2025
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
Tue, 21 Jan 2025
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
Mon, 13 Jan 2025
NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire
Mon, 13 Jan 2025
NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan
Wed, 08 Jan 2025
NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 51.2 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.77 |
| Profit Margin | 0 % |
| Operating Margin | -360.9 % |
| Return on Assets (ttm) | -260.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -5.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.33 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | -3.9 |
| Price to Sales | 9.03 |
| Price to Cash Flow | -2.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|